News and Press Releases
Psyence Group Completes Export Of Pharma Grade Psilocybin Extract To UK
Psyence announce that it has exported purified pharmaceutical grade psilocybin mushroom extract to its Contract Development & Manufacturing Organisation (“CDMO”) partner in the United Kingdom.
Psyence Announces Business Combination between Wholly Owned Subsidiary Psyence Biomed Corp. and Nasdaq listed Newcourt Acquisition Corp
Psyence & Newcourt have entered into a definitive business combination agreement (the “Business Combination Agreement”) on January 9, 2023 with Psyence Biomed Corp (“Psyence Biomed”), a wholly owned subsidiary of Psyence, to create a public company (the “Combined Company”) leveraging natural psilocybin in the treatment of palliative care (the “Business Combination”). Psyence Biomed is Psyence’s clinical trial division.
Psyence Signs Letter of Intent with Australian CRO iNGENū
Psyence announce it has signed a Letter of Intent (LOI) with Contract Research Organisation (CRO) iNGENū to execute Psyence’s strategy of clinical development in palliative care. iNGENū is an Australian full-service CRO specialising in clinical trials for psychoactive pharmaceuticals.